Last updated: August 1, 2026
Rosiglitazone maleate and glimepiride are the active ingredients in GlaxoSmithKline's Avandaryl, an oral fixed-dose combination for type 2 diabetes. The FDA approved Avandaryl in 2006, but the product has no meaningful current clinical-development pipeline, limited commercial visibility, and substantial competitive pressure from low-cost generic monotherapies and newer diabetes medicines. The principal barriers are rosiglitazone's cardiovascular and fluid-retention warnings, declining use of thiazolidinediones, and the absence of a differentiated delivery system.
What is rosiglitazone maleate and glimepiride?
Rosiglitazone is a thiazolidinedione that improves insulin sensitivity through PPAR-gamma activation. Glimepiride is a sulfonylurea that increases pancreatic insulin secretion. The combination targets two mechanisms of hyperglycemia but also combines the safety liabilities of both classes.
| Product characteristic |
Description |
| Brand |
Avandaryl |
| Active ingredients |
Rosiglitazone maleate and glimepiride |
| Original sponsor |
GlaxoSmithKline |
| FDA application |
NDA 021925 |
| Dosage form |
Oral tablet |
| Strengths |
4 mg/1 mg, 4 mg/2 mg, 4 mg/4 mg, 8 mg/2 mg, and 8 mg/4 mg |
| Primary indication |
Type 2 diabetes inadequately controlled on rosiglitazone or glimepiride monotherapy |
| FDA approval |
2006 |
| Drug classes |
Thiazolidinedione plus sulfonylurea |
Avandaryl was intended for patients already receiving one component and requiring combination therapy. It was not positioned as a first-line treatment for most patients.
What clinical trials evaluated rosiglitazone and glimepiride?
The pivotal evidence for Avandaryl came from controlled studies of rosiglitazone added to sulfonylurea therapy and from studies of glimepiride added to rosiglitazone. These trials generally measured hemoglobin A1c and fasting plasma glucose over periods of approximately 24 weeks.
Efficacy findings
Combination therapy produced greater glucose reduction than either component alone in patients inadequately controlled on monotherapy. The expected pharmacology was confirmed:
- Rosiglitazone improved insulin sensitivity.
- Glimepiride increased insulin secretion.
- HbA1c reduction was greater than with either agent alone in selected patients.
- Hypoglycemia and weight gain increased relative to rosiglitazone monotherapy.
- Edema and fluid retention remained clinically relevant because of rosiglitazone.
The clinical value of the combination was later weakened by safety concerns involving rosiglitazone and by the availability of metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin products.
What are the major safety concerns?
The FDA label carries a boxed warning for congestive heart failure. Rosiglitazone can cause or worsen fluid retention and is contraindicated in patients with New York Heart Association class III or IV heart failure. Glimepiride can cause severe hypoglycemia, particularly in elderly patients, patients with renal or hepatic impairment, and those with inconsistent food intake (FDA, 2023a).
Other relevant risks include:
- Weight gain
- Edema
- Bone fractures, particularly in women
- Macular edema reports
- Hypoglycemia
- Potential cardiovascular risk concerns associated with rosiglitazone
- Possible bladder-cancer risk considerations in the broader rosiglitazone safety literature
The RECORD cardiovascular-outcomes study did not establish a statistically significant increase in the primary cardiovascular endpoint, but its findings did not eliminate clinical concern regarding rosiglitazone's risk-benefit profile (Home et al., 2009).
What is the FDA regulatory status of Avandaryl?
Avandaryl remains an FDA-approved combination product based on its NDA history, but its commercial availability has materially declined. The FDA removed special dispensing restrictions for rosiglitazone in 2013 after reviewing additional cardiovascular data, while retaining label warnings and risk information (FDA, 2013).
The FDA regulatory position is therefore different from a market-success position:
| Regulatory issue |
Status |
| Original approval |
Approved |
| Combination indication |
Retained in labeling |
| Cardiovascular boxed warning |
Retained |
| REMS restrictions |
Removed in 2013 |
| Generic component availability |
Broad for rosiglitazone and glimepiride individually |
| Current clinical development |
No material late-stage program publicly associated with the combination |
The product's regulatory approval does not imply active commercial promotion or broad formulary access.
What patents protect rosiglitazone maleate and glimepiride?
The principal composition-of-matter and combination-product patent estate has largely expired. Rosiglitazone and glimepiride are both established generic ingredients, and the commercial exclusivity that once supported Avandaryl has ended.
Patent and exclusivity position
| Asset category |
Commercial position |
| Rosiglitazone active ingredient |
Loss of original exclusivity |
| Glimepiride active ingredient |
Loss of original exclusivity |
| Fixed-dose combination |
No meaningful remaining U.S. market exclusivity identified |
| Formulation protection |
No differentiated current formulation platform of commercial significance |
| Method-of-use protection |
Any surviving claims would face limited value because the underlying drugs are generic |
| Biosimilar protection |
Not applicable; both ingredients are small molecules |
Avandaryl is not a biologic, so biosimilar litigation and biologic interchangeability rules do not apply. Generic-drug competition is governed primarily by the Abbreviated New Drug Application pathway and, where relevant, Paragraph IV certifications.
Are there Paragraph IV challenges to Avandaryl?
The commercial importance of Paragraph IV litigation for Avandaryl is limited because the active ingredients and the principal combination opportunity are mature. Generic competition has focused more heavily on rosiglitazone and glimepiride as separate products than on a high-value branded combination.
A Paragraph IV certification can challenge an Orange Book-listed patent before expiration. The business case for a challenge depends on remaining patent life, expected market size, litigation cost, and whether the reference product has meaningful prescriptions. For Avandaryl, the small and declining market reduces the expected return from a complex patent challenge.
What is the Orange Book status of rosiglitazone and glimepiride?
The FDA Orange Book lists approved drug products and relevant patent or exclusivity information. Avandaryl's Orange Book relevance is primarily historical because its commercial period of protected value has passed. Rosiglitazone tablets and glimepiride tablets are available through generic approvals, while the combination has substantially less commercial traction than the separate ingredients (FDA, 2024).
The key Orange Book implications are:
- No biologic reference-product framework applies.
- Any remaining listed patent must be assessed against actual enforceability and expiration.
- Generic applicants can rely on the mature safety and efficacy record of the reference products.
- The combination does not have the market protection associated with a newly approved fixed-dose therapy.
How strong is the patent estate for rosiglitazone and glimepiride?
The patent estate is weak from a commercial-protection perspective. The underlying pharmacology is old, the ingredients are generic, and the product lacks a newer formulation, device, or manufacturing platform that could support a meaningful second-generation exclusivity strategy.
Patent strength can be assessed across four dimensions:
| Dimension |
Assessment |
| Composition of matter |
Expired or commercially exhausted |
| Fixed-dose combination |
Limited remaining value |
| Method of use |
Narrow practical value in a crowded diabetes market |
| Manufacturing process |
Potentially relevant to cost control, not broad market exclusivity |
| Formulation innovation |
No established differentiated platform |
| Litigation leverage |
Low |
Process patents could still protect a particular salt, impurity profile, particle-size distribution, or manufacturing method. Such claims would not necessarily prevent generic companies from using alternative processes.
What formulations are protected by Avandaryl?
Avandaryl is an immediate-release oral tablet. Its value was based on combining two established active ingredients rather than on an extended-release system, injectable delivery method, depot formulation, or device.
The formulation strategy offered convenience by reducing pill burden. It did not create a strong technological barrier because a patient could obtain the same pharmacologic components through separate generic tablets. This substitution risk limits the commercial value of fixed-dose combination patents after basic product exclusivity expires.
What patent litigation affects rosiglitazone and glimepiride?
No major current litigation campaign is associated with the combination that materially changes the market outlook. Historical litigation and regulatory disputes involving rosiglitazone focused more heavily on cardiovascular safety, labeling, and broader product liability than on an active patent-enforcement strategy.
The relevant legal risk has shifted from patent exclusion to:
- Product-liability exposure
- Labeling obligations
- Formulary restrictions
- Generic substitution
- Reimbursement pressure
- Declining physician use
When did rosiglitazone lose exclusivity?
Rosiglitazone lost meaningful U.S. market exclusivity after the expiration of its core patents and the subsequent entry of generic products. Glimepiride also has long been generic. Avandaryl therefore operates, where available, in a post-exclusivity market.
| Milestone |
Approximate timing |
| Rosiglitazone launched as Avandia |
1999 |
| Avandaryl approved |
2006 |
| Major rosiglitazone safety restrictions |
2010-2011 |
| FDA REMS restrictions removed |
2013 |
| Generic rosiglitazone availability |
2012 onward |
| Current commercial position |
Mature, low-growth, generic-dominated |
Exact product availability varies by country, manufacturer, pharmacy channel, and inventory status.
How does rosiglitazone/glimepiride compare with competing diabetes drugs?
Avandaryl faces stronger competition from both inexpensive generic combinations and newer branded medicines with outcome advantages.
| Therapy |
Main advantage |
Main disadvantage relative to Avandaryl |
| Metformin plus sulfonylurea |
Low cost and extensive use |
Hypoglycemia and weight gain |
| Metformin plus DPP-4 inhibitor |
Low hypoglycemia risk |
Higher cost; less potent HbA1c reduction |
| GLP-1 receptor agonist |
Weight loss and strong glucose lowering |
Injection or high acquisition cost for many products |
| SGLT2 inhibitor |
Heart-failure and renal benefits for selected patients |
Genitourinary adverse effects and cost |
| Basal insulin |
High glucose-lowering potency |
Hypoglycemia, monitoring, and weight gain |
| Rosiglitazone plus glimepiride |
Low-cost oral dual mechanism |
Edema, weight gain, hypoglycemia, cardiovascular limitations |
Current diabetes guidelines generally favor therapies with cardiovascular, renal, or weight benefits for patients with relevant comorbidities. That trend disadvantages rosiglitazone-based combinations (American Diabetes Association Professional Practice Committee, 2024).
What is the market outlook for rosiglitazone maleate and glimepiride?
The market is a mature generic market with limited expansion potential. No credible growth thesis exists for Avandaryl absent a new safety, pricing, or formulation strategy.
Market drivers
Potential demand is supported by:
- Low ingredient cost
- Oral administration
- Familiarity in price-sensitive markets
- Use where newer therapies are unavailable or unaffordable
- Existing experience with both ingredients
Market constraints
The principal constraints are:
- Generic availability of both components
- Ability to prescribe the components separately
- Rosiglitazone's cardiovascular and edema warnings
- Hypoglycemia and weight gain from glimepiride
- Competition from low-cost metformin-based regimens
- Increasing use of GLP-1 and SGLT2 therapies
- Weak branded reimbursement
- Limited active promotion
- Lack of current clinical differentiation
What is the five-year commercial projection?
The most defensible projection is for flat-to-declining revenue in developed markets and selective, price-driven use in emerging markets. A product-specific revenue forecast cannot be reliably derived from public data because current branded sales disclosure is limited and the combination is not a major reported revenue line for its original sponsor.
Scenario projection
| Scenario |
Five-year outlook |
Commercial interpretation |
| Base case |
Decline of 5% to 12% annually in branded-equivalent demand |
Continued generic substitution and prescriber attrition |
| Downside case |
Decline above 12% annually |
Further formulary exclusion and discontinuation in additional markets |
| Upside case |
Flat to low-single-digit growth in selected low-cost markets |
Access-driven use, not innovation-driven expansion |
The combination could retain a niche where drug cost dominates treatment selection. It is unlikely to regain meaningful share in the U.S. or other markets where cardiovascular-risk management and weight reduction influence prescribing.
What generic launch risks exist?
Generic entry risk is high, but it is not the only commercial threat. The combination competes against separate generic tablets, which can produce equivalent or lower total treatment cost and allow dose adjustment of each ingredient.
A potential generic entrant would face:
- Low expected market size
- Limited brand loyalty
- Price erosion
- Reference-product availability questions
- Manufacturing economics that favor separate components
- Safety-label scrutiny
- Minimal opportunity for premium pricing
The main risk to any remaining branded demand is substitution by generic rosiglitazone plus generic glimepiride rather than a direct fixed-dose generic.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest. Both active ingredients have established synthetic routes and mature quality-control methods. Potential technical issues include impurity control, polymorphism, content uniformity, dissolution, and stability of the fixed-dose tablet.
These issues can delay approval or increase manufacturing cost, but they do not create a durable market barrier comparable to a biologic manufacturing platform or complex drug-delivery device.
What licensing deals involve rosiglitazone and glimepiride?
No current high-value licensing transaction materially changes the outlook for the combination. The product originated within GlaxoSmithKline's diabetes portfolio. Any later rights transfers or local commercialization arrangements would be market-specific and would not restore global exclusivity.
The commercial logic of licensing is strongest in countries where:
- Rosiglitazone remains approved,
- low-cost oral therapy is preferred,
- local distribution is established, and
- regulatory access is more important than clinical differentiation.
Key Takeaways
- Avandaryl combines rosiglitazone maleate and glimepiride in an immediate-release tablet.
- The FDA approved the product in 2006 under NDA 021925.
- No material current clinical-trial program supports commercial re-expansion.
- Rosiglitazone's cardiovascular, heart-failure, edema, and weight-gain warnings constrain use.
- Glimepiride adds hypoglycemia and weight-gain risk.
- Core exclusivity has expired, and both ingredients are available generically.
- The combination has weak remaining patent leverage and no biosimilar opportunity.
- Current market prospects are mature and declining in developed markets.
- Any residual growth is likely to be access-driven in price-sensitive markets.
- The principal competitive threat is generic use of the two ingredients separately, followed by newer therapies with cardiovascular, renal, and weight-management benefits.
FAQs
Is Avandaryl still marketed in the United States?
Avandaryl has limited current commercial visibility in the United States. Availability depends on manufacturer supply, pharmacy inventory, and market-specific distribution.
Can rosiglitazone and glimepiride be taken as separate generic tablets?
The two ingredients can be prescribed separately, subject to clinical judgment and FDA-approved labeling. Separate dosing provides greater flexibility and is often less expensive than maintaining a branded fixed-dose combination.
Is rosiglitazone contraindicated in heart failure?
Rosiglitazone is contraindicated in patients with NYHA class III or IV heart failure and carries a boxed warning concerning congestive heart failure.
Does rosiglitazone/glimepiride have biosimilar competition?
No. Both ingredients are small-molecule drugs. Competition comes through generic-drug applications, not biosimilar applications.
Could a new formulation revive the product?
A new extended-release, low-hypoglycemia, or targeted-delivery formulation could create a separate intellectual-property opportunity, but it would require new clinical evidence and would still face rosiglitazone's established safety liabilities.
References
-
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.
-
Food and Drug Administration. (2013). FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023a). Avandaryl (rosiglitazone maleate and glimepiride) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes. The Lancet, 373(9681), 2125-2135.
